MiR-29a Inhibits Glioma Tumorigenesis Through a Negative Feedback Loop of TRAF4/Akt Signaling

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Sep 7

PMID 30186853

Citations 14

Authors

Yongjie Liu

Naiquan Duan

Shibo Duan

Affiliations

Soon will be listed here.

Abstract

Background: MiR-29a is known as a repressor of human cancer. However, its relevance in glioma proliferation and invasion remains largely unknown. In this study, we aimed to investigate the function and mechanism of miR-29a in glioma tumorigenesis.

Methods: The expression of miR-29a was determined by using qRT-PCR. CCK-8, wound healing, and transwell invasion assays were carried out to analyze the effects of miR-29a in glioblastoma cells. qRT-PCR, luciferase reporter, and western blot experiments were done to validate the targeting of TRAF4/Akt pathway by miR-29a. The expression correlation between levels of TRAF4 and miR-29a was analyzed. Regulation of miR-29a expression by enhanced/reduced TRAF4/Akt expression was finally confirmed by qRT-PCR.

Results: MiR-29a was decreased in the glioma tissues, especially in those at higher grades. Following its mimic transfection, we validated that miR-29a inhibited cell proliferation, migration, and invasion. Consistently, miR-29a inhibition induced the opposite effects on cell proliferation, migration, and invasion. We confirmed TRAF4 as a direct target of miR-29a, which might mediate the Akt pathway activation. We showed a significantly negative expression correlation between TRAF4 and miR-29a in normal and glioma tissues. Finally we observed an upregulation of miR-29a in TRAF4/Akt activated cells.

Conclusion: MiR-29a is critical tumor suppressor for glioma tumorigenesis by forming a negative feedback loop of TRAF4/Akt signaling and represents a potent therapeutic candidate for treating gliomas.

Citing Articles

TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway.

Li J, Wang C, Xiao W, Chen Y, Tu J, Wan F J Am Heart Assoc. 2023; 12(17):e028185.

PMID: 37642020 PMC: 10547335. DOI: 10.1161/JAHA.122.028185.

Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling.

Lu J, Zhao Q, Guo Y, Li D, Xie H, Liu C J Exp Clin Cancer Res. 2023; 42(1):93.

PMID: 37081505 PMC: 10116798. DOI: 10.1186/s13046-023-02665-6.

Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects.

Hatmal M, Al-Hatamleh M, Olaimat A, Alshaer W, Hasan H, Albakri K Biomedicines. 2022; 10(6).

PMID: 35740242 PMC: 9219990. DOI: 10.3390/biomedicines10061219.

TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling.

Iyengar P, Marvin D, Lama D, Tan T, Suriyamurthy S, Xie F Mol Cancer Res. 2022; 20(10):1516-1531.

PMID: 35731212 PMC: 9530648. DOI: 10.1158/1541-7786.MCR-20-1029.

The Research Progress in Physiological and Pathological Functions of TRAF4.

Ruan X, Zhang R, Li R, Zhu H, Wang Z, Wang C Front Oncol. 2022; 12:842072.

PMID: 35242717 PMC: 8885719. DOI: 10.3389/fonc.2022.842072.

References

Goodenberger M, Jenkins R . Genetics of adult glioma. Cancer Genet. 2012; 205(12):613-21. DOI: 10.1016/j.cancergen.2012.10.009. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Wang Z, Zhang M, Deng M, Weng N, Wang H, Wu S . Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. PLoS One. 2017; 12(9):e0184969. PMC: 5607158. DOI: 10.1371/journal.pone.0184969. View

Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View

Jiang H, Zhang G, Wu J, Jiang C . Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014; 31(4):1509-16. DOI: 10.3892/or.2014.3036. View

Ostrom Q, Gittleman H, Stetson L, Virk S, Barnholtz-Sloan J . Epidemiology of gliomas. Cancer Treat Res. 2014; 163:1-14. DOI: 10.1007/978-3-319-12048-5_1. View

Ames H, Halushka M, Rodriguez F . miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. J Neuropathol Exp Neurol. 2017; 76(4):246-254. DOI: 10.1093/jnen/nlx005. View

Chen J, Yang L, Wang X . Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma. Cancer Biomark. 2017; 20(4):521-526. DOI: 10.3233/CBM-170335. View

Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo J . Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. Cell Rep. 2016; 16(6):1527-1535. PMC: 4981543. DOI: 10.1016/j.celrep.2016.07.017. View

10.

Arch R, Gedrich R, Thompson C . Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. Genes Dev. 1998; 12(18):2821-30. DOI: 10.1101/gad.12.18.2821. View

11.

Chen J, Deng S, Zhang S, Chen Z, Wu S, Cai X . The role of miRNAs in the differentiation of adipose-derived stem cells. Curr Stem Cell Res Ther. 2014; 9(3):268-79. DOI: 10.2174/1574888x09666140213203309. View

12.

Xu H, Sun J, Shi C, Sun C, Yu L, Wen Y . miR-29s inhibit the malignant behavior of U87MG glioblastoma cell line by targeting DNMT3A and 3B. Neurosci Lett. 2015; 590:40-6. DOI: 10.1016/j.neulet.2015.01.060. View

13.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

14.

Li W, Peng C, Lee M, Lim D, Zhu F, Fu Y . TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 2013; 73(23):6938-50. PMC: 3856436. DOI: 10.1158/0008-5472.CAN-13-0913. View

15.

Liu K, Wu X, Zang X, Huang Z, Lin Z, Tan W . TRAF4 Regulates Migration, Invasion, and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Hepatocellular Carcinoma. Oncol Res. 2017; 25(8):1329-1340. PMC: 7841052. DOI: 10.3727/096504017X14876227286564. View

16.

Regnier C, Tomasetto C, Moog-Lutz C, Chenard M, Wendling C, Basset P . Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem. 1995; 270(43):25715-21. DOI: 10.1074/jbc.270.43.25715. View

17.

Manning B, Cantley L . AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-74. PMC: 2756685. DOI: 10.1016/j.cell.2007.06.009. View

18.

Yao W, Wang X, Cai Q, Gao S, Wang J, Zhang P . TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway. Oncol Res. 2015; 22(1):21-28. PMC: 7592778. DOI: 10.3727/096504014X14077751730351. View

19.

Amodio N, Rossi M, Raimondi L, Pitari M, Botta C, Tagliaferri P . miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2015; 6(15):12837-61. PMC: 4536984. DOI: 10.18632/oncotarget.3805. View

20.

Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J . Primary brain tumours in adults. Lancet. 2012; 379(9830):1984-96. DOI: 10.1016/S0140-6736(11)61346-9. View